Head and Neck Cancer, Lip Cancer, Oral Cancer, Pharynx Cancer
Conditions
Brief summary
This study aims to determine whether dysbiosis actively contributes to HNSCC and if so, the underlying molecular mechanisms.
Detailed description
HNSCCis a lethal cancer with a 5-year survival rate below 50%. Although smoking, alcohol intake, and human papillomavirus (HPV) infection are linked to HNSCC, only a small proportion of individuals exposed to these factors develop cancer and not all cases progress. Thus, additional environmental or host factors must contribute to HNSCC. The Study Team and others have observed significant oral dysbiosis in human HNSCC cases, both before and after treatment. This study aims to determine whether dysbiosis actively contributes to HNSCC and if so, the underlying molecular mechanisms.
Interventions
DIAGNOSTIC_TESTMetagenomic sequencing
Shotgun metagenomic sequencing will characterize cancer-associated changes in microbial functional capacity and species/strain-level taxonomic profiles. Metagenomics will provide data on microbial functional capacity along with broader taxonomic classifications.
DIAGNOSTIC_TESTMetabolic analysis
Metabolic analysis will be conducted using LC/MS-based metabolic analysis. A targeted approach will quantify a panel of 30 compounds including Trp pathway products while a non-targeted approach, when applied to both lipid and aqueous phase compounds, will profile relative changes in compounds that may influence host
Sponsors
University of Colorado, Denver
National Cancer Institute (NCI)
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Inclusion criteria
1. Subjects equal to or above the age of 18. 2. Patients who are seen and evaluated by a provider within the adult Otolaryngology clinic at the University of Colorado Health. 3. Patients that present with a diagnosis of OSCC. 4. An equal number of age-matched patients who are visiting the clinic for reasons other than OSCC diagnoses, as the control group. 5. Ability to understand and willingness to sign a written informed consent document
Exclusion criteria
1. Subjects under the age of 18 or over the age of 100 2. Subjects unwilling to particiapte
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Characterize human dysbiosis | Day 1 | Stool and saliva samples will be collected from participants, allowing us to reproduce human dysbiosis and analyze whether HNSCC affects one's microbiome composition. Metagenomic sequencing will be conducted through use of DNA extraction, library generation and Illumina sequencing. At least 30 million paired-end 2x150bp metagenomic reads will be generated per sample using the Illumina NovaSeq platform. |
| Characterize human metabolomics | Day 1 | Through our stool and saliva samples we will be able to characterize metagenomic and metabolic signatures in treatment naïve OSCC and non-OSCC patients. Metabolic analysis will be conducted using LC/MS-based metabolic analysis. A targeted approach will quantify a panel of 30 componds including Trp pathway products, while a non-targeted approach, when applied to both lipid and aqueous phase compounds, will profile relative changes in compounds that may influence host and metabolic and immune statuses. |
| Integrative multi-omic data analysis and biomarker discovery | Day 365 | We expect to find that specific sets of microbial and host factors interact with each other to promote OSCC. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Impact of human dysbiosis on OSCC development in mice | Day 10-Day 100 | Freshly collected saliva and stool samples from 10 subjects of each treatment category will be used to reconstitute microbiota. |
| Monitor tumor size | Day 10-Day 100 | Tumor size (both weight and size) will be monitored using Bli-imaging. These measures will be assessed between treatment groups by ANOVA or analysis of variance testing. |
Countries
United States
Contacts
CONTACTYosr Doghri
CONTACTKristi Engle Folchert
PRINCIPAL_INVESTIGATORShi-Long E Lu, MD, PhD
University of Colorado, Denver
Outcome results
None listed